Aphaia Pharma

Aphaia Pharma is a clinical-stage biopharmaceutical company harnessing proprietary precision-targeted drug formulations to restore endogenous hormone release from nutrient-sensing cells in the GI tract to treat and prevent metabolic disorders such as obesity and associated diseases. Aphaia’s lead candidate, APH-012, a glucose formulation, has been shown to safely restore endogenous hormone release in individuals with obesity. APH-012 is now being evaluated in a Phase 2 trial in the U.S. and Germany for chronic weight management and is preparing to be evaluated in a second Phase 2 trial for the improvement of pre-diabetes in individuals with a pathological oral glucose tolerance test (OGTT). The versatile design of Aphaia’s technology platform provides an opportunity for the development of treatments for multiple disease patterns.